AbCellera Biologics Inc.
ABCL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABCL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABCL
AbCellera Biologics Inc. is a biotechnology company focused on antibody drug discovery and development, advancing a pipeline of internal programs and partnering with other companies to bring antibody therapeutics from target to clinical testing.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.68B
Cash Runway
—
Lead Asset
ABCL575 (Phase 1/Phase 2)
Next Catalyst
Phase2_Topline · Sep 30, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for AbCellera Biologics Inc..
AbCellera Biologics Inc. is a biotechnology company focused on antibody drug discovery and development, advancing a pipeline of internal programs and partnering with other companies to bring antibody therapeutics from target to clinical testing.
- As of June 30, 2026, AbCellera had $540.1 million in cash, cash equivalents, and marketable securities [sec_mda · as of 2026-08-05].
- The company reported a net loss of $55.4 million for the six months ended June 30, 2026 [latest reported financials (as of 2026-06-30)].
- AbCellera's partner-led programs with downstreams decreased from 44 as of December 31, 2025 to 35 as of June 30, 2026 [sec_mda · as of 2026-08-05].
- The company is advancing its internal program ABCL635, with Phase 2 enrollment underway and top-line clinical results anticipated in Q3 2026 [sec_mda · as of 2026-02-24].
- Total shareholders' equity was $966.9 million as of June 30, 2026 [latest reported financials (as of 2026-06-30)].
What works
- AbCellera holds a strong cash position of $540.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a substantial runway for operations and clinical development [sec_mda · as of 2026-08-05].
- The company has a robust discovery platform and a history of partner-initiated program starts, with 103 cumulative partner-initiated program starts with downstreams as of September 30, 2025 [sec_mda · as of 2025-11-06].
- AbCellera is advancing its internal pipeline, including ABCL635 in a Phase 2 trial for vasomotor symptoms, with top-line results expected in Q3 2026, which could be a value-driving milestone [sec_mda · as of 2026-02-24].
What to weigh
- AbCellera reported a net loss of $55.4 million for the six months ended June 30, 2026, reflecting ongoing operating expenses and investment in R&D without corresponding revenue from approved products [latest reported financials (as of 2026-06-30)].
- The number of partner-led programs with downstreams declined from 44 as of December 31, 2025 to 35 as of June 30, 2026, indicating potential attrition in partnered pipeline [sec_mda · as of 2026-08-05].
- The company's long-term financial success is dependent on successfully transitioning drug candidates from discovery through clinical development, which requires significant financial investment and carries inherent risk of failure [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
AbCellera had $540.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
“As of June 30, 2026, we had $540.1 million of cash, cash equivalents and marketable securities, comprising $120.1 million in cash and cash equivalents and $420.0 million in marketable securities.”
SEC MD&A · August 5, 2026
Partner-led programs with downstreams decreased from 44 to 35 between December 31, 2025 and June 30, 2026.
“Partner-led programs with downstreams | | 44 | | | 35”
SEC MD&A · August 5, 2026
Top-line clinical results for ABCL635 are anticipated in Q3 2026.
“With Phase 2 enrollment underway, we anticipate top-line clinical results for both phases in Q3 2026.”
SEC MD&A · February 24, 2026
Catalyst timeline
- 2026-09-30 · Phase2_Topline · abcl635 — Phase 2 Readout: abcl635 — Top-line results from the Phase 2 portion of the ABCL635 trial for vasomotor symptoms are expected, which will provide initial efficacy and safety data.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Success of internal programs like ABCL635 is uncertain; clinical trials may fail, impacting value [sec_mda · as of 2026-08-05].
- Partner program attrition — Partner-led programs decreased from 44 to 35 in six months, indicating potential pipeline shrinkage [sec_mda · as of 2026-08-05].
- Continued net losses — Net loss of $55.4M in H1 2026 shows ongoing cash burn without product revenue [latest reported financials (as of 2026-06-30)].
- Dependence on partnerships — Revenue and pipeline rely on partner collaborations, which may not be sustained [sec_mda · as of 2025-11-06].
What to watch
- Top-line Phase 2 results for ABCL635 expected in Q3 2026, which could be a key value driver [sec_mda · as of 2026-02-24].
- Changes in partner-led program count and new partnership announcements, as attrition may signal pipeline challenges [sec_mda · as of 2026-08-05].
- Cash burn rate and any updates on liquidity, given the net loss and reliance on cash reserves [latest reported financials (as of 2026-06-30)].
- Progress of internal pipeline programs beyond ABCL635, as long-term success depends on clinical execution [sec_mda · as of 2026-08-05].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run AbCellera Biologics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AbCellera Biologics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.46 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
1 upcoming, next in ~31d
4 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
133
Total value held
$311.4M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 30,275,938 | $105.7M |
| two sigma investments, lp | 10,562,065 | $36.9M |
| jefferies financial group inc. | 5,482,400 | $19.1M |
| blackrock, inc. | 4,040,236 | $14.1M |
| driehaus capital management llc | 4,024,779 | $14.0M |
| goldman sachs group inc | 3,751,212 | $13.1M |
| bank of america corp /de/ | 2,999,936 | $10.5M |
| alyeska investment group, l.p. | 2,592,105 | $9.0M |
| tudor investment corp et al | 2,273,489 | $7.9M |
| morgan stanley | 2,224,829 | $7.8M |
Showing top 10 of 133 institutional holders of AbCellera Biologics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 18.9%
- Days to cover
- 8.8
- Shares short
- 44,457,643
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABCL short interestGovernance
Frequently asked questions
What is the AI investment thesis for AbCellera Biologics Inc.?
AbCellera Biologics Inc. is a biotechnology company focused on antibody drug discovery and development, advancing a pipeline of internal programs and partnering with other companies to bring antibody therapeutics from target to clinical testing.
What is AbCellera Biologics Inc.'s lead drug candidate?
AbCellera Biologics Inc.'s most advanced tracked candidate is ABCL575 (Phase 1/Phase 2) for Healthy Volunteers.
What is AbCellera Biologics Inc.'s next catalyst?
AbCellera Biologics Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: abcl635" — expected September 30, 2026.
Who is the CEO of AbCellera Biologics Inc.?
Dr. Carl L.G. Hansen Ph.D. is the chief executive officer of AbCellera Biologics Inc. (ABCL).
Where is AbCellera Biologics Inc. headquartered?
AbCellera Biologics Inc. (ABCL) is headquartered in Vancouver, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.